An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Descrición completa

Detalles Bibliográficos

Principais autores:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2025-07-01
Series:	EBioMedicine
Assuntos:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!